Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Just Group doubles profit two years ahead of schedule

(Sharecast News) - Just Group shares snapped violently lower at the end of the week, after the financial services group reported full-year profits that fell short of analysts' estimates by a wide margin. For over 2024, Just Group said that its adjusted pre-tax profit fell by 7.3% to reach £482m, a result that it attributed to lower non-operating items.

Group chief David Richardson however stressed the positives, saying: "We made a pledge three years ago to double profits over five years.

"We have significantly exceeded that target in just three years and created substantial shareholder value as a result."

Underlying operating profit on the other hand was ahead by 34% to £504m.

Management cited new business sales growth, higher recurring in-force profit and more scale.

The company's total dividend per share rose by 20% to 2.5p, thanks to a 1.8p final pay-out.

"Underlying operating profit was broadly in line, but represented growth of 34% yoy, while the 20% DPS growth and 204% SII ratios were both ahead of consensus," analysts at RBC said in a research note sent to clients.

"We remain constructive on JUST's growth outlook, and updating our model for results supports incremental underlying operating profit upgrades of 2%/3% for FY25/26, with a corresponding increase in our PT to 200p (from 190p). Reiterate Outperform."

As of 0910 BST, shares of Just Group were trading 15.32% lower at 138.20p, having been knocked down from their seven-year highs.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.